about
Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell linesAssessment of drug transporter function using fluorescent cell imagingMutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.A high-throughput cell-based assay for inhibitors of ABCG2 activity.Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerizationSide population analysis using a violet-excited cell-permeable DNA binding dye.Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.New inhibitors of ABCG2 identified by high-throughput screeningABCG2 is expressed in late spermatogenesis and is associated with the acrosome.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Botryllamides: natural product inhibitors of ABCG2Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaIcotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.Arginine 383 is a crucial residue in ABCG2 biogenesisReduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.Survivin is not induced by novel taxanes.A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.Rapid detection of ABC transporter interaction: potential utility in pharmacology.The challenge of exploiting ABCG2 in the clinic.ABCG2: a perspective.Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.Histone deacetylase inhibitors: emerging mechanisms of resistance.A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cellsLoss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.The controversial role of ABC transporters in clinical oncology.Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe.Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
P50
Q28483816-386309D4-E9CF-4C3E-B964-F192C6675ECAQ30571452-3EDE00DF-095C-4A00-A164-715FAB3508E2Q33194953-D2605073-BFBF-4C37-95D3-29B925C3978CQ33234390-D416298B-F764-4689-B1FF-2671DC2788CBQ33240063-CEEE3DA2-8E2C-4BFE-B2E9-E88A80C56A1FQ33267436-952E3B79-8A3A-435C-A648-3FAF9F02E1CFQ33285468-CBF272DF-20B1-4540-8612-3C4D91D8BA1AQ33311099-3B927E42-912A-42F7-AFE3-78D2D946F0AFQ33387095-10E19ADE-E9B6-4FFC-9FD4-7940A4B54EBDQ33390876-40C7FBCC-F4EF-4D3E-90AA-8F3B633CCB78Q33474489-44D89944-7ED9-4142-9718-CDA751969767Q33566582-4D6F6077-D092-4CC8-91A2-4E5A0E7B8FAFQ33718824-74A4E888-FF31-479F-BE19-CD7EFA903452Q33726989-4DD51743-BCC8-45D4-9FAB-E52710E67B78Q34101040-031731C0-5031-46B3-A88E-0A66E5BF91D6Q34180165-C01714B5-AFE2-4924-AC80-920885E49FA1Q34385596-D3602CDD-EB9A-4A24-8FCB-33D95BF15C9AQ34415628-6C5CAF4F-9DF8-473D-9BFD-718F951E5242Q34523239-7A17B45F-3676-4F1D-931F-B0A245D2D785Q34743441-868C7B3A-2AD3-4277-963A-BC7F49E12CC5Q34768677-AAE83238-FD5D-46F3-89E0-BE556242E285Q34803651-8A5A0DF8-E35B-473B-9A66-D9D95EDF7925Q34913068-53274BD5-FC1A-421B-A546-5FF51965D37EQ34968909-1B35171B-7E7E-40CE-922F-FC88571F1803Q35016817-A640396C-5796-4782-876F-46B8CDE75E79Q35062586-94E5F6B0-9E58-482A-AC3D-F7E61AFFE8B3Q35592607-FF0613EB-4076-4DA5-8451-0D5D64FB761AQ35913254-8496F473-1AAC-4233-9710-A68218E2F593Q36283075-4E3AB527-A492-409C-AB87-5CF0134C5E2EQ36920272-BCC5CDE4-997A-4292-B9D0-D9E0A2A39F6FQ37020542-E75C5121-A184-4C6A-8F03-0CB80C6E4A00Q37074550-FCB0F74E-F1C0-41B4-A165-654E24B61E58Q37119716-0F23BA7D-9C43-43CD-A57D-6850FC4ABEFEQ37219909-DC87B191-5CBD-497E-B044-EEA66844D5CAQ37505528-AAC2EFF0-0AE0-45B5-9B41-D87CDC50CE97Q37684405-BDD2404D-43C3-4224-B2AE-56CC6F0EAC45Q37941758-A214C548-E120-4A1B-90B6-051A0A82822CQ38471153-E3709B85-4A5F-4F73-9F1A-E562AD845408Q38696056-F7CDEB54-60A7-4F04-89A5-E587B2DBE5F9Q39004891-41228A5C-6B05-4975-BB14-9381E8B67904
P50
description
researcher ORCID ID = 0000-0002-0857-3650
@en
wetenschapper
@nl
name
Rob Robey
@ast
Rob Robey
@en
Rob Robey
@es
Rob Robey
@nl
type
label
Rob Robey
@ast
Rob Robey
@en
Rob Robey
@es
Rob Robey
@nl
prefLabel
Rob Robey
@ast
Rob Robey
@en
Rob Robey
@es
Rob Robey
@nl
P106
P1153
7005143185
P31
P496
0000-0002-0857-3650